AU2001258536A1 - Derivatisation of proteins in aqueous solution - Google Patents

Derivatisation of proteins in aqueous solution

Info

Publication number
AU2001258536A1
AU2001258536A1 AU2001258536A AU5853601A AU2001258536A1 AU 2001258536 A1 AU2001258536 A1 AU 2001258536A1 AU 2001258536 A AU2001258536 A AU 2001258536A AU 5853601 A AU5853601 A AU 5853601A AU 2001258536 A1 AU2001258536 A1 AU 2001258536A1
Authority
AU
Australia
Prior art keywords
derivatization
groups
denaturant
vivo
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258536A
Other languages
English (en)
Inventor
Gregory Gregoriadis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipoxen Technologies Ltd
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Publication of AU2001258536A1 publication Critical patent/AU2001258536A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AU2001258536A 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution Abandoned AU2001258536A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00304108.4 2000-05-16
EP00304108 2000-05-16
PCT/GB2001/002115 WO2001087922A2 (en) 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution

Publications (1)

Publication Number Publication Date
AU2001258536A1 true AU2001258536A1 (en) 2001-11-26

Family

ID=8172993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258536A Abandoned AU2001258536A1 (en) 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution

Country Status (8)

Country Link
US (1) US6962972B2 (enExample)
EP (1) EP1335931B1 (enExample)
JP (1) JP2003533537A (enExample)
AT (1) ATE313554T1 (enExample)
AU (1) AU2001258536A1 (enExample)
DE (1) DE60116137T2 (enExample)
ES (1) ES2256234T3 (enExample)
WO (1) WO2001087922A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294535T3 (es) 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
EP1654290B1 (en) * 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8652334B2 (en) 2004-08-12 2014-02-18 Lipoxen Technologies Limited Fractionation of charged polysaccharide
EP3184551A1 (en) 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialic acid derivatives
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US8217154B2 (en) 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
US8299015B2 (en) * 2006-07-25 2012-10-30 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
EP2409995A3 (en) 2007-02-28 2012-08-15 Lipoxen Technologies Limited Reduction of endotoxin in polysialic acids
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
EP3093029A1 (en) * 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
TR201908836T4 (tr) 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
JP2014520094A (ja) 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
CN113817069A (zh) 2013-06-28 2021-12-21 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
HUE057005T2 (hu) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
CU20170038A7 (es) 2014-09-26 2017-10-05 Bayer Pharma AG Derivados de adrenomedulina estabililzados especialmente útiles en el tratamiento y/o prevención de trastornos cardiovasculares, edematosos y/o inflamatorios
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
SG11201804666QA (en) 2015-12-03 2018-06-28 Baxalta Inc Factor viii with extended half-life and reduced ligand-binding properties
BR112018070459A2 (pt) 2016-04-04 2019-02-12 Shire Human Genetic Therapies, Inc. inibidor da c1 esterase conjugado e usos do mesmo
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
EP3986918A1 (en) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process

Also Published As

Publication number Publication date
WO2001087922A3 (en) 2003-05-30
ATE313554T1 (de) 2006-01-15
ES2256234T3 (es) 2006-07-16
DE60116137D1 (de) 2006-01-26
US20030129159A1 (en) 2003-07-10
EP1335931A2 (en) 2003-08-20
DE60116137T2 (de) 2006-08-24
WO2001087922A2 (en) 2001-11-22
JP2003533537A (ja) 2003-11-11
US6962972B2 (en) 2005-11-08
EP1335931B1 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
AU2001258536A1 (en) Derivatisation of proteins in aqueous solution
Pinkus [45] Glutamine binding sites
Börner et al. Molybdopterin adenine dinucleotide and molybdopterin hypoxanthine dinucleotide in formylmethanofuran dehydrogenase from Methanobacterium thermoautotrophicum (Marburg)
MA23825A1 (fr) Synthese d'activateurs de blanchiment
EA199900980A1 (ru) Улучшенные способы приготовления активированного белка с
Roveri et al. PHGPx and spermatogenesis
DE69621953D1 (de) Vehikel zum einbringen von nukleinsäuren in zellen
BR9910307A (pt) Enzimas de trigo, que codificam moléculas de ácidos nucléicos, que tomam parte na sìntese de amido
BR9612006A (pt) Processo para fabricar uma solução aquosa contendo pelo menos 30 por cento em peso de ácido (met) acrílico ou sal do mesmo e abaixo de 0,2% de (met) acrilonitrila
ES2152813B1 (es) Productos celulares de poliuretano de celulas abiertas.
ES2136418T3 (es) Determinacion de proteinas glicosiladas.
ES2076398T3 (es) Procedimiento para la preparacion de sales de la l-ornitina.
BR0115418A (pt) Processo
Dannenberg Jr et al. Histochemical demonstration of hydrogen peroxide production by leukocytes in fixed‐frozen tissue sections of inflammatory lesions
Ranieri-Raggi et al. Effects of storage on activity and subunit structure of rabbit skeletal-muscle AMP deaminase
BR9712575A (pt) Processo para restaurar em células que apresentam uma proteìna p53 que sofreu mutação , uma atividade de transactivação p53-dependente, utilizações de um anticorpo de cadeia simples capaz de ligar especificamente uma proteìna p53 que sofreu mutação, e de um ácido nucleico codificante, molécula 11d3 ou uma variante, ácido nucleico e composição
ES2079442T3 (es) Oxidacion enzimatica mejorada de cef c a acido glutaril-7-amino-cefalosporanico.
Al-Timari et al. Inhibition by glutathione derivatives of bovine liver glyoxalase II (hydroxyacylglutathione hydrolase) as a probe of the N-and S-sites for substrate binding
NO20003880D0 (no) Transfekterende midler som er sensitive overfor reduserende betingelser, farmasøytiske preparater inneholdende disse samt deres anvendelser
EP1474526A4 (en) ENZYME ACTIVATION PROTEASE ASSAY
Aukerman et al. Effect of plasma and carboxylesterase on the stability, mutagenicity, and DNA cross-linking activity of some direct-acting N-nitroso compounds
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
PT979036E (pt) Concentrado enzimatico
García-Carreño et al. Control of digestive functions in shrimp, I. An inhibitor of trypsin activity in the hepatopancreas
NOMURA et al. Effect of modification of sulfhydryl groups in soybean β-amylase on the interaction with substrate and inhibitors